Myeloproliferative Neoplasms

 449

An update on the phase 4 EXELS study of cytoreductive therapies in patients with essential thrombocythaemia

Prof Claire Harrison

The Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) is a phase 4 clinical study, designed to monitor the safety of anagrelide and other cytoreductive therapies in patients with essential thrombocythaemia in routine clinical practice. At the 20th Congress of the European Hematology Association (EHA), Prof Claire Harrison, Consultant Haematologist and Deputy Director at Guy's and St Thomas' NHS Foundation Trust, London, UK, tells us about the positive findings of the trial to date.

See all videos from: